Helsinn links with Grünenthal for Akynzeo marketing in Chile

Privately-held Swiss drugmaker Helsinn and Grünenthal Group have signed an exclusive agreement for the registration, marketing, promotion and sales by Grupo Grünenthal Chile of Akynzeo, the oral fixed combination of netupitant and palonosetron, developed for the prevention of chemotherapy-induced nausea and vomiting (CINV), in the Chilean market.

This agreement bolsters an already strong partnership between Helsinn and Grünenthal, a German family-owned pharmaceutical group focused especially on pain, central nervous System, Women´s Health and Diversified Products. Financial terms of the latest deal were not disclosed.

Under the terms of the agreement, Helsinn retains clinical development, international regulatory activities and the manufacturing and supply of Akynzeo. Grünenthal will have exclusive rights to registration, marketing, promotion and sales of Akynzeo in Chile. Akynzeo is already approved in the USA, the European Union, Switzerland, Israel and Australia.